The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Open accessAbstract
We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficient in their ability to recruit C1q to the surface of CD20-positive cells and mediate tumor lysis via activation of the classical pathway of complement. This complement-dependent cytotoxicity (CDC) potency appeared to relate to the unusually slow off-rate of these human Abs. However, we now present epitope-mapping data, which indicates that all human mAb bind a novel region of CD20 that may influence CDC potency. Epitope mapping, using both mutagenesis studies and overlapping 15-mer peptides of the extracellular loops of CD20, defined the amino acids required for binding by an extensive panel of mouse and human mAb. Binding by rituximab and mouse CD20 mAb, had an absolute requirement for alanine and proline at positions 170 and 172, respectively, within the large extracellular loop of CD20. Surprisingly, however, all of the human CD20 mAb recognize a completely novel epitope located N-terminally of this motif, also including the small extracellular loop of CD20. Thus, although off-rate may influence biological activity of mAb, another critical factor for determining CDC potency by CD20 mAb appears to be the region of the target molecule they recognize. We conclude that recognition of the novel epitope cooperates with slow off-rate in determining the activity of CD20 Ab in activation of complement and induction of tumor cell lysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Self-citationCD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
Self-citationSignaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385
Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v99.3.1038 · Cited by 367
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
Self-citationMonoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Press, O., Appelbaum, F., Ledbetter, J., Martin, P., Zarling, J., Kidd, P., & Thomas, E. (1987) · Blood · doi:10.1182/blood.v69.2.584.584 · Cited by 361
Laskey, R. A., Fairman, M. P., & Blow, J. J. (1989) · Science · doi:10.1126/science.2683076 · Cited by 361
Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359
Cited by
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationDevelopment trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
Self-citationBuilding better monoclonal antibody-based therapeutics
Weiner, G. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3930 · Cited by 712
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Self-citationChronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Hallek, M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25595 · Cited by 504
Complement-targeted therapeutics
Ricklin, D., & Lambris, J. D. (2007) · Nature Biotechnology · doi:10.1038/nbt1342 · Cited by 481
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., Marin, V., Marafioti, T., Chakraverty, R., Linch, D., et al. (2014) · Blood · doi:10.1182/blood-2014-01-545020 · Cited by 397
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
Rodgers, D. T., Mazagova, M., Hampton, E. N., Cao, Y., Ramadoss, N. S., Hardy, I. R., Schulman, A., Du, J., Wang, F., Singer, O., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524155113 · Cited by 397
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Hallek, M., & Al‐Sawaf, O. (2021) · American Journal of Hematology · doi:10.1002/ajh.26367 · Cited by 393
Klein, C., Lammens, A., Schäfer, W., Georges, G., Schwaiger, M., Mössner, E., Hopfner, K.-P., Umaña, P., & Niederfellner, G. (2013) · mAbs · doi:10.4161/mabs.22771 · Cited by 392
Coiffier, B., Lepretre, S., Pedersen, L. M., Gadeberg, O., Fredriksen, H., van Oers, M. H. J., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., et al. (2008) · Blood · doi:10.1182/blood-2007-09-111781 · Cited by 387
Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1182 · Cited by 366
Dighiero, G., & Hamblin, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60456-0 · Cited by 366
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Hillmen, P., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., Doubek, M., Panagiotidis, P., Kimby, E., Schuh, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60027-7 · Cited by 343
Beers, S. A., French, R. R., Chan, H. T. C., Lim, S. H., Jarrett, T. C., Vidal, R. M., Wijayaweera, S. S., Dixon, S. V., Kim, H., Cox, K. L., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263533 · Cited by 335
Self-citationAntibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., Shimada, K., Chan, C. H. T., Tutt, A., Beers, S. A., et al. (2011) · Blood · doi:10.1182/blood-2010-07-296913 · Cited by 294
Self-citationChronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Hallek, M. (2017) · American Journal of Hematology · doi:10.1002/ajh.24826 · Cited by 282
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
Targeted drug delivery for cancer therapy: the other side of antibodies
Firer, M. A., & Gellerman, G. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-70 · Cited by 269
B‐cell Therapy for Multiple Sclerosis: Entering an era
Greenfield, A. L., & Hauser, S. L. (2018) · Annals of Neurology · doi:10.1002/ana.25119 · Cited by 265
Hagenbeek, A., Gadeberg, O., Johnson, P., Møller Pedersen, L., Walewski, J., Hellmann, A., Link, B. K., Robak, T., Wojtukiewicz, M., Pfreundschuh, M., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117671 · Cited by 264
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment
Hallek, M. (2015) · American Journal of Hematology · doi:10.1002/ajh.23979 · Cited by 263
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., & Taylor, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900632 · Cited by 262
Self-citationEngelberts, P. J., Hiemstra, I. H., de Jong, B., Schuurhuis, D. H., Meesters, J., Beltran Hernandez, I., Oostindie, S. C., Neijssen, J., van den Brink, E. N., Horbach, G. J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102625 · Cited by 172
Self-citationLessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
Golay, J., Semenzato, G., Rambaldi, A., Foà, R., Gaidano, G., Gamba, E., Pane, F., Pinto, A., Specchia, G., Zaja, F., et al. (2013) · mAbs · doi:10.4161/mabs.26008 · Cited by 148
Dandamudi, D. B., Konieczna, I. M., Calabrese, K. M., Wielgos-Bonvallet, M., Kweekel, C., Gresnigt-van den Heuvel, E., Iyer, R., Ellis, P., Rodriguez, L., Parikh, A., et al. (2025) · Leukemia & Lymphoma · doi:10.1080/10428194.2025.2504719 · Cited by 5
Metadata
- Authors
- Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., Parren, P. W. H. I., Glennie, M. J., & van de Winkel, J. G. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07-01
- Volume
- 177
- Issue
- 1
- Pages
- 362-371
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2122725450
- Cited by
- 609
- References
- 41
- FWCI
- 22.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.